Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D001058:Apomorphine / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D004327:Drinking Behavior; D004558:Electric Stimulation; D004576:Electromyography; D005247:Feeding Behavior; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology*; D007980:Levodopa / Q000627:therapeutic use; D009046:Motor Neurons / Q000503:physiopathology; D009119:Muscle Contraction; D009410:Nerve Degeneration / Q000187:drug effects*; D009434:Neural Pathways; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010468:Perceptual Disorders / Q000139:chemically induced; D051381:Rats; D012026:Reflex, Stretch; D013378:Substantia Nigra / Q000187:drug effects* / Q000502:physiology
D006892:Hydroxydopamines; D007980:Levodopa; D000661:Amphetamine; D001058:Apomorphine